Washington, District of Columbia
United States
114
2025-03-20
110
2025-11-25
These are the the leading inventors for applications assigned to Vanda Pharmaceuticals, Inc.:
Vanda Pharmaceuticals, Inc. based in Washington, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
METHOD OF TREATMENT WITH MILSAPERIDONE
#2 | 2025-03-20 ✅ Patent 12,447,141 granted on 2025-10-21Liquid Tasimelteon Formulations and Methods of Use Thereof
#3 | 2024-10-10 ✅ Patent 12,304,896 granted on 2025-05-20Highly purified pharmaceutical grade tasimelteon
#4 | 2024-08-29 ✅ Patent 12,419,869 granted on 2025-09-23Methods Of Treating Multiple Sclerosis
#5 | 2024-05-16 ✅ Patent 12,201,604 granted on 2025-01-21Treatment of circadian rhythm disorders
#6 | 2024-05-02 ✅ Patent 12,527,772 granted on 2026-01-20PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD
#7 | 2024-05-02 ✅ Patent 12,409,167 granted on 2025-09-09PHARMACEUTICAL COMBINATION COMPRISING A SELECTIVE S1P1 RECEPTOR AGONIST
#8 | 2023-11-30 ✅ Patent 12,049,457 granted on 2024-07-30Highly purified pharmaceutical grade tasimelteon
#9 | 2023-11-23 ✅ Patent 12,440,470 granted on 2025-10-14Liquid Tasimelteon Formulations and Methods of Use Thereof
#10 | 2023-11-16 ✅ Patent 12,622,915 granted on 2026-05-12METHODS OF TREATING PDE IV-MEDIATED DISEASES OR CONDITIONS
#11 | 2023-08-17 ✅ Patent 12,590,162 granted on 2026-03-31CANCER TREATMENT
#12 | 2023-07-06 ✅ Patent 11,918,557 granted on 2024-03-05Treatment of circadian rhythm disorders
#13 | 2023-06-22 ✅ Patent 12,544,367 granted on 2026-02-10METHOD OF TREATMENT OF SCHIZOPHRENIA
#14 | 2023-05-18 ✅ Patent 11,760,740 granted on 2023-09-19Highly purified pharmaceutical grade tasimelteon
#15 | 2023-05-11 ✅ Patent 12,582,640 granted on 2026-03-24TREATMENT OF LOWER RESPIRATORY TRACT INFECTION WITH TRADIPITANT
#16 | 2023-05-11 ✅ Patent 11,951,097 granted on 2024-04-09Methods of treating multiple sclerosis
#17 | 2023-04-27 ✅ Patent 12,336,980 granted on 2025-06-24DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
#18 | 2023-04-13 ✅ Patent 12,357,616 granted on 2025-07-15Methods Of Treating Multiple Sclerosis
#19 | 2023-01-26Ophthalmic Pharmaceutical Compositions
#20 | 2022-12-08 ✅ Patent 12,427,132 granted on 2025-09-30METHOD OF IMPROVING SLEEP
#21 | 2022-12-01 ✅ Patent 12,403,134 granted on 2025-09-02METHOD FOR IMPROVING OR ENHANCING COGNITION
#22 | 2022-09-22 ✅ Patent 12,201,583 granted on 2025-01-21Pharmaceutical dosage system
#23 | 2022-09-01 ✅ Patent 12,502,379 granted on 2025-12-23METHODS OF TREATING MULTIPLE SCLEROSIS
#24 | 2022-07-21 ✅ Patent 12,318,375 granted on 2025-06-03Method of treatment with tradipitant
#25 | 2022-06-09 ✅ Patent 11,826,339 granted on 2023-11-28Treatment of circadian rhythm disorders
#26 | 2022-06-02 ✅ Patent 11,918,556 granted on 2024-03-05Treatment of circadian rhythm disorders
#27 | 2022-06-02 ✅ Patent 11,850,229 granted on 2023-12-26Treatment of circadian rhythm disorders
#28 | 2022-03-17 ✅ Patent 12,146,185 granted on 2024-11-19Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
#29 | 2022-03-10 ✅ Patent 11,566,011 granted on 2023-01-31Highly purified pharmaceutical grade tasimelteon
#30 | 2022-02-10 ✅ Patent 11,458,116 granted on 2022-10-04Method of improving sleep
#31 | 2021-12-09 ✅ Patent 11,786,502 granted on 2023-10-17Method of treatment
#32 | 2021-10-28 ✅ Patent 11,285,129 granted on 2022-03-29Treatment of circadian rhythm disorders
#33 | 2021-10-21 ✅ Patent 11,667,718 granted on 2023-06-06Cancer treatment
#34 | 2021-10-21 ✅ Patent 11,723,903 granted on 2023-08-15Treatment of schizophrenia
#35 | 2021-09-09 ✅ Patent 11,845,990 granted on 2023-12-19Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype
#36 | 2021-07-15 ✅ Patent 11,759,446 granted on 2023-09-19Liquid tasimelteon formulations and methods of use thereof
#37 | 2021-07-08 ✅ Patent 11,833,130 granted on 2023-12-05Treatment of circadian rhythm disorders
#38 | 2021-06-17 ✅ Patent 11,202,770 granted on 2021-12-21Liquid tasimelteon formulations and methods of use thereof
#39 | 2021-06-03 ✅ Patent 11,633,377 granted on 2023-04-25Treatment of circadian rhythm disorders
#40 | 2021-04-15 ✅ Patent 11,607,408 granted on 2023-03-21Method of treatment of schizophrenia
#41 | 2021-03-04 ✅ Patent 11,549,147 granted on 2023-01-10Treatment of atopic dermatitis with tradipitant
#42 | 2021-01-21 ✅ Patent 11,203,581 granted on 2021-12-21Highly purified pharmaceutical grade tasimelteon
#43 | 2020-12-24 ✅ Patent 11,433,057 granted on 2022-09-06Method for improving or enhancing cognition
#44 | 2020-11-19 ✅ Patent 11,324,735 granted on 2022-05-10Method of treatment with tradipitant
#45 | 2020-07-30 ✅ Patent 11,266,622 granted on 2022-03-08Method of treatment
#46 | 2020-06-18 ✅ Patent 10,829,465 granted on 2020-11-10Highly purified pharmaceutical grade tasimelteon
#47 | 2020-06-18 ✅ Patent 11,141,400 granted on 2021-10-12Method of treatment
#48 | 2020-06-11 ✅ Patent 10,980,770 granted on 2021-04-20Treatment of circadian rhythm disorders
#49 | 2020-04-02 ✅ Patent 10,821,099 granted on 2020-11-03Use of tradipitant in motion sickness
#50 | 2020-03-05 ✅ Patent 11,214,827 granted on 2022-01-04Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
#51 | 2020-01-09 ✅ Patent 10,945,988 granted on 2021-03-16Treatment of circadian rhythm disorders
#52 | 2020-01-09 ✅ Patent 11,737,993 granted on 2023-08-29Multiple myeloma treatment
#53 | 2019-12-26 ✅ Patent 10,987,346 granted on 2021-04-27Iloperidone for the treatment of schizophrenia
#54 | 2019-11-07 ✅ Patent 10,610,511 granted on 2020-04-07Method of treatment
#55 | 2019-09-26 ✅ Patent 10,772,880 granted on 2020-09-15Method of treatment with tradipitant
#56 | 2019-07-11 ✅ Patent 11,078,289 granted on 2021-08-03Cancer treatment
#57 | 2019-05-09 ✅ Patent 11,090,285 granted on 2021-08-17Treatment of circadian rhythm disorders
#58 | 2019-04-11 ✅ Patent 10,653,665 granted on 2020-05-19Method of treatment
#59 | 2019-03-07 ✅ Patent 10,610,510 granted on 2020-04-07Treatment of circadian rhythm disorders
#60 | 2019-01-03 ✅ Patent 10,611,744 granted on 2020-04-07Highly purified pharmaceutical grade tasimelteon
#61 | 2018-09-13 ✅ Patent 10,265,282 granted on 2019-04-23Cancer treatment
#62 | 2018-08-23 ✅ Patent 10,570,453 granted on 2020-02-25Method of predicting a predisposition to QT prolongation
#63 | 2018-04-26 ✅ Patent 10,272,076 granted on 2019-04-30Methods for the administration of iloperidone
#64 | 2018-04-26 ✅ Patent 10,463,655 granted on 2019-11-05Method of treatment with tradipitant
#65 | 2018-04-12 ✅ Patent 10,233,142 granted on 2019-03-19Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
#66 | 2018-03-15 ✅ Patent 10,449,176 granted on 2019-10-22Treatment of circadian rhythm disorders
#67 | 2018-01-25 ✅ Patent 10,441,580 granted on 2019-10-15Iloperidone for the treatment of schizophrenia
#68 | 2018-01-04 ✅ Patent 10,563,261 granted on 2020-02-18Method of predicting a predisposition to QT prolongation
#69 | 2018-01-04 ✅ Patent 10,570,452 granted on 2020-02-25Method of predicting a predisposition to QT prolongation
#70 | 2018-01-04 ✅ Patent 10,563,260 granted on 2020-02-18Method of predicting a predisposition to QT prolongation
#71 | 2017-08-24 ✅ Patent 10,179,119 granted on 2019-01-15Method of treatment
#72 | 2017-07-06 ✅ Patent 10,071,977 granted on 2018-09-11Highly purifid pharmaceutical grade tasimelteon
#73 | 2017-06-22 ✅ Patent 9,850,199 granted on 2017-12-26Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
#74 | 2017-06-15 ✅ Patent 11,071,728 granted on 2021-07-27Treatment of schizophrenia
#75 | 2017-06-15 ✅ Patent 11,013,713 granted on 2021-05-25Method of treatment
#76 | 2017-04-13 ✅ Patent 10,149,829 granted on 2018-12-11Treatment of circadian rhythm disorders
#77 | 2017-03-30 ✅ Patent 9,855,241 granted on 2018-01-02Treatment of circadian rhythm disorders
#78 | 2017-03-30 ✅ Patent 10,376,487 granted on 2019-08-13Method of treatment
#79 | 2016-12-15 ✅ Patent 9,987,264 granted on 2018-06-05Method and composition for treating a serotonin receptor-mediated condition
#80 | 2016-09-15 ✅ Patent 9,458,507 granted on 2016-10-04Antipsychotic treatment based on SNP genotype
#81 | 2016-08-04TREATING NEURODEGENERATIVE DISEASE WITH FENOFIBRATE AND ANALOGS THEREOF
#82 | 2016-07-28 ✅ Patent 11,458,154 granted on 2022-10-04Treatment of CYR61- and VEGF-mediated conditions
#83 | 2016-06-16 ✅ Patent 9,408,839 granted on 2016-08-09Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
#84 | 2016-03-03 ✅ Patent 9,708,291 granted on 2017-07-18Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl)-(2-chlorophenyl)-methanone
#85 | 2016-03-03 ✅ Patent 9,617,203 granted on 2017-04-11Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
#86 | 2015-08-06 ✅ Patent 9,539,234 granted on 2017-01-10Treatment of circadian rhythm disorders
#87 | 2015-07-16 ✅ Patent 10,376,487 granted on 2019-08-13METHOD OF TREATMENT
#88 | 2015-06-18 ✅ Patent 9,157,121 granted on 2015-10-13Method of treatment based on polymorphisms of the KCNQ1 gene
#89 | 2015-05-28 ✅ Patent 9,212,129 granted on 2015-12-15Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
#90 | 2015-02-12 ✅ Patent 10,874,659 granted on 2020-12-29Iloperidone metabolite for use in the treatment of psychiatric disorders
#91 | 2015-01-22 ✅ Patent 9,730,910 granted on 2017-08-15Treatment of circadian rhythm disorders
#92 | 2014-12-04 ✅ Patent 9,549,913 granted on 2017-01-24Treatment of circadian rhythm disorders
#93 | 2014-10-02 ✅ Patent 9,060,995 granted on 2015-06-23Treatment of circadian rhythm disorders
#94 | 2014-07-10 ✅ Patent 10,272,075 granted on 2019-04-30Method and composition for treating an alpha adrenoceptor-mediated condition
#95 | 2014-05-08 ✅ Patent 9,138,432 granted on 2015-09-22Methods for the administration of iloperidone
#96 | 2014-03-20 ✅ Patent 9,446,038 granted on 2016-09-20Method and composition for treating a serotonin receptor-mediated condition
#97 | 2014-02-13METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
#98 | 2014-02-06METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
#99 | 2013-08-01 ✅ Patent 8,785,492 granted on 2014-07-22Treatment of circadian rhythm disorders
#100 | 2013-01-24 ✅ Patent 8,558,017 granted on 2013-10-15Ruthenium (II) catalysts for use in stereoselective cyclopropanations
Also check out Vanda Pharmaceuticals Inc.'s (Washington, United States) applicant profile with 133 patent applications submitted.
32832 ⎘